1. Malloch D, Salkin IF. A new species of Scedosporium associated with osteomyelitis in humans. Mycotaxon. 1984; 21:247–255.
2. Marco de Lucas E, Sádaba P, Lastra García-Barón P, Ruiz Delgado ML, Cuevas J, Salesa R, et al. Cerebral scedosporiosis: an emerging fungal infection in severe neutropenic patients: CT features and CT pathologic correlation. Eur Radiol. 2006; 16:496–502.
Article
3. Rodriguez-Tudela JL, Berenguer J, Guarro J, Kantarcioglu AS, Horre R, de Hoog GS, et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol. 2009; 47:359–370.
Article
4. Idigoras P, Pérez-Trallero E, Piñeiro L, Larruskain J, López-Lopategui MC, Rodríguez N, et al. Disseminated infection and colonization by Scedosporium prolificans: a review of 18 cases, 1990-1999. Clin Infect Dis. 2001; 32:E158–E165.
Article
5. Ong A, Blyth CC, Bency R, Vicaretti M, Harun A, Meyer W, et al. Fatal mycotic aneurysms due to Scedosporium and Pseudoallescheria infection. J Clin Microbiol. 2011; 49:2067–2071.
Article
6. Díaz-Valle D, Benitez del Castillo JM, Amor E, Toledano N, Carretero MM, Díaz-Valle T. Severe keratomycosis secondary to Scedosporium apiospermum. Cornea. 2002; 21:516–518.
Article
7. National Medical Advisory Board of the National Multiple Sclerosis Society. Recommendations regarding corticosteroids in the management of multiple sclerosis. US Neurology. 2008; 4:22–24.
8. Franchin G, Diamond B. Pulse steroids: how much is enough? Autoimmun Rev. 2006; 5:111–113.
Article